Aditxt, Inc. (NASDAQ:ADTX) Short Interest Up 102.2% in October

Aditxt, Inc. (NASDAQ:ADTX) was the recipient of a significant growth in short interest in the month of October. As of October 31st, there was short interest totalling 910,800 shares, a growth of 102.2% from the October 15th total of 450,400 shares. Approximately 10.4% of the shares of the company are sold short. Based on an average daily trading volume, of 2,420,000 shares, the short-interest ratio is currently 0.4 days.

Insiders Place Their Bets

In other news, major shareholder Financial Lp Hrt sold 25,534 shares of the business’s stock in a transaction on Wednesday, October 16th. The shares were sold at an average price of $1.17, for a total transaction of $29,874.78. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 1.72% of the stock is owned by corporate insiders.

Aditxt Price Performance

Shares of ADTX stock opened at $0.35 on Thursday. The business has a 50 day simple moving average of $6.35 and a 200 day simple moving average of $42.99. Aditxt has a 12-month low of $0.34 and a 12-month high of $380.00.

Aditxt (NASDAQ:ADTX) last issued its quarterly earnings results on Monday, August 19th. The company reported ($167.60) EPS for the quarter. The firm had revenue of $0.04 million during the quarter.

Aditxt Company Profile

Aditxt, Inc, a biotech company, engages in the development and commercialization of technologies that focus on improving the health through monitoring and modulating the immune systems. The company develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its tissues.